Table 1.
Baseline characteristics of participants
| Ceftriaxone group (n=362) | Gentamicin group (n=358) | ||
|---|---|---|---|
| Mean age, years (SD) | 30·2 (10·1) | 30·4 (9·9) | |
| Gender | |||
| Female | 69 (19%) | 65 (18%) | |
| Male | 293 (81%) | 292 (82%) | |
| Other | 0 | 1 (<1%) | |
| Ethnicity | |||
| White | 241 (67%) | 255 (71%) | |
| Black | 53 (15%) | 48 (13%) | |
| Asian | 26 (7%) | 18 (5%) | |
| Mixed race | 27 (7%) | 26 (7%) | |
| Other | 15 (4%) | 11 (3%) | |
| Country of birth | |||
| UK | 258 (71%) | 253 (71%) | |
| Europe (excluding UK) | 51 (14%) | 56 (16%) | |
| North America | 8 (2%) | 5 (1%) | |
| Asia Pacific | 18 (5%) | 14 (4%) | |
| Latin America | 7 (2%) | 11 (3%) | |
| Middle East | 2 (1%) | 5 (1%) | |
| Africa | 18 (5%) | 14 (4%) | |
| Creatinine (μmol/L) | |||
| Mean (SD) | 78·6 (15·4) | 78·3 (15·8) | |
| Range | 42–137 | 26–154 | |
| n | 343 | 332 | |
| Estimated glomerular filtration rate | |||
| Mean (SD) | 110·6 (18·2) | 111·5 (17·7) | |
| Range | 56·3–179 | 52·4–157·7 | |
| n | 341 | 328 | |
| Medical history* | |||
| Diabetes | 3 (1%) | 1 (<1%) | |
| Otitis media | 9 (2%) | 7 (2%) | |
| Renal disease | 3 (1%) | 4 (1%) | |
| Liver disease | 8 (2%) | 5 (1%) | |
| Gonorrhoea | 152 (42%) | 142 (40%) | |
| Chlamydia | 121 (33%) | 127 (35%) | |
| Syphilis | 48 (13%) | 53 (15%) | |
| Pelvic inflammatory disease (women) | 2/69 (3%) | 2/65 (3%) | |
| HIV status (participant self-report) | |||
| Positive | 53 (15%) | 43 (12%) | |
| Unknown | 10 (3%) | 8 (2%) | |
| Sites of infection | |||
| Genital | 190 (52%) | 219 (61%) | |
| Pharyngeal | 128 (35%) | 128 (36%) | |
| Rectal | 159 (44%) | 147 (41%) | |
| Number of sites infected | |||
| One | 189 (52%) | 180 (50%) | |
| Two | 96 (27%) | 94 (26%) | |
| Three | 32 (9%) | 42 (12%) | |
| Positive diagnosis of gonorrhoea at baseline visit | 317 (87%) | 316 (88%) | |
| Positive diagnosis of gonorrhoea by Gram stain at baseline visit | 139/224 (38%) | 166/239 (46%) | |
| Positive diagnosis of gonorrhoea by nucleic acid amplification test at baseline visit† | 308/358 (86%) | 309/353 (88%) | |
Data are n (%) unless otherwise specified.
*
Medical history was based on the participant ever having had that condition.
†
Data not available for four participants in the ceftriaxone group and five in the gentamicin group.